冠心病患者治疗前后血清NO/NOS和PGMP检测的临床意义  

Clinical Significance of Determination of Changes of Serum NO,NOS and Platelet Granular Membrane Protein (PGMP) Contents After Treatment in Patients with Coronary Heart Disease

作　　者：金文涛[1] 朱卫金[1] 薛宏峰[1] 

机构地区：[1]江苏省常州市中医院检验科,213002

出　　处：《放射免疫学杂志》2007年第6期528-529,共2页Journal of Radioimmanology

摘　　要：目的:探讨了冠心病患者治疗前后血清NO/NOS和血小板α-颗粒膜蛋白(PGMP)水平的变化及意义。方法:应用酶法和放免法测定了40例冠心病患者血清NO、NOS和PGMP含量,并与35名正常健康人作比较。结果:冠心病患者在治疗前血清NO水平显著地低于正常人组(P<0.01),而NOS、PGMP水平又非常显著地高于正常人组(P<0.01),经治疗后6个月血NO、NOS水平与正常人组比较无显著性差异(P>0.05),而PGMP与正常人组比较仍有显著性差异(P<0.05)。结论:冠心病的发生、发展与血NO/NOS和PGMP水平密切相关。Objective To explore the clinical significance of changes of serum NO, NOS and PGMP levels in patients with coronary heart disease after treatment. Methods Serum NO, NOS （with enzyme method） and PGMP （with RIA） contents were measured in 40 patients with coronary heart disease both before and after treatment as well as in 35 controls. Results Before treatment, serum levels of NO were significantly lower （ P 〈 0.01 ） in patients with coronary heart disease but serum NOS and PGMP levels were signifieanfly higher（ P 〈 0.01 ） than those in the controls. After treatment for six months, the serum levels of NO and NOS in the patients were not much different from those in the controls（P 〉0.05）, but serum PGMP levels remained significantly higher（ P 〈0.05）. Conclusion Serum NO, NOS and PGMP levels might be of prognostic value in patients with coronary heart disease.

关 键 词：冠心病 一氧化氮 一氧化氮酶 血小板Α-颗粒膜蛋白 

分 类 号：R446.61[医药卫生—诊断学]